Header Logo

Connection

Jill Macoska to Male

Back to Details
This is a "connection" page, showing publications Jill Macoska has written about Male.
Jill Macoska
Connection Strength
0.856
Male
  1. D'Arcy Q, Sarna-McCarthy M, Bowen D, Soto FO, Zarringhalam K, Macoska JA. Beta-Sitosterol Alters Collagen Distribution in Prostate Fibroblasts. J Diet Suppl. 2024; 21(3):313-326.
    View in: PubMed
    Score: 0.047
  2. D'Arcy Q, Gharaee-Kermani M, Zhilin-Roth A, Macoska JA. The IL-4/IL-13 signaling axis promotes prostatic fibrosis. PLoS One. 2022; 17(10):e0275064.
    View in: PubMed
    Score: 0.043
  3. Tantiwetrueangdet A, Panvichian R, Sornmayura P, Leelaudomlipi S, Macoska JA. PCNA-associated factor (KIAA0101/PCLAF) overexpression and gene copy number alterations in hepatocellular carcinoma tissues. BMC Cancer. 2021 Mar 20; 21(1):295.
    View in: PubMed
    Score: 0.039
  4. Macoska JA, Uchtmann KS, Leverson GE, McVary KT, Ricke WA. Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study. J Urol. 2019 12; 202(6):1240-1247.
    View in: PubMed
    Score: 0.034
  5. Macoska JA, Wang Z, Virta J, Zacharias N, Bjorling DE. Inhibition of the CXCL12/CXCR4 axis prevents periurethral collagen accumulation and lower urinary tract dysfunction in vivo. Prostate. 2019 05; 79(7):757-767.
    View in: PubMed
    Score: 0.034
  6. Macoska JA. Androgen receptor variants: another twist in the plot. Oncotarget. 2017 03 07; 8(10):16100.
    View in: PubMed
    Score: 0.029
  7. Rodr?guez-Nieves JA, Patalano SC, Almanza D, Gharaee-Kermani M, Macoska JA. CXCL12/CXCR4 Axis Activation Mediates Prostate Myofibroblast Phenoconversion through Non-Canonical EGFR/MEK/ERK Signaling. PLoS One. 2016; 11(7):e0159490.
    View in: PubMed
    Score: 0.028
  8. Gharaee-Kermani M, Moore BB, Macoska JA. Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion. PLoS One. 2016; 11(7):e0158357.
    View in: PubMed
    Score: 0.028
  9. Gharaee-Kermani M, Mehra R, Robinson DR, Wei JT, Macoska JA. Complex cellular composition of solitary fibrous tumor of the prostate. Am J Pathol. 2014 Mar; 184(3):732-9.
    View in: PubMed
    Score: 0.024
  10. Gharaee-Kermani M, Macoska JA. Promising molecular targets and biomarkers for male BPH and LUTS. Curr Urol Rep. 2013 Dec; 14(6):628-37.
    View in: PubMed
    Score: 0.023
  11. Rodriguez-Nieves JA, Macoska JA. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol. 2013 Sep; 10(9):546-50.
    View in: PubMed
    Score: 0.023
  12. Gharaee-Kermani M, Rodriguez-Nieves JA, Mehra R, Vezina CA, Sarma AV, Macoska JA. Obesity-induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse model. Prostate. 2013 Jul; 73(10):1123-33.
    View in: PubMed
    Score: 0.022
  13. Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA. CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS One. 2012; 7(11):e49278.
    View in: PubMed
    Score: 0.022
  14. Agarwal M, He C, Siddiqui J, Wei JT, Macoska JA. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate. 2013 May; 73(6):573-81.
    View in: PubMed
    Score: 0.022
  15. Ma J, Gharaee-Kermani M, Kunju L, Hollingsworth JM, Adler J, Arruda EM, Macoska JA. Prostatic fibrosis is associated with lower urinary tract symptoms. J Urol. 2012 Oct; 188(4):1375-81.
    View in: PubMed
    Score: 0.021
  16. Kasina S, Macoska JA. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol. 2012 Apr 04; 351(2):249-63.
    View in: PubMed
    Score: 0.021
  17. Macoska JA. Chemokines and BPH/LUTS. Differentiation. 2011 Nov-Dec; 82(4-5):253-60.
    View in: PubMed
    Score: 0.020
  18. McDowell KL, Begley LA, Mor-Vaknin N, Markovitz DM, Macoska JA. Leukocytic promotion of prostate cellular proliferation. Prostate. 2010 Mar 01; 70(4):377-89.
    View in: PubMed
    Score: 0.018
  19. Macoska JA, Begley LA, Dunn RL, Siddiqui J, Wei JT, Sarma AV. Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA. Prostate. 2008 Mar 01; 68(4):442-52.
    View in: PubMed
    Score: 0.016
  20. Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA. CXCL5 promotes prostate cancer progression. Neoplasia. 2008 Mar; 10(3):244-54.
    View in: PubMed
    Score: 0.016
  21. Begley LA, MacDonald JW, Day ML, Macoska JA. CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J Biol Chem. 2007 Sep 14; 282(37):26767-26774.
    View in: PubMed
    Score: 0.015
  22. Macoska JA. Ancestry, genetic susceptibility, E-cadherin-160A and prostate cancer risk-is there an association? J Urol. 2006 Aug; 176(2):435-6.
    View in: PubMed
    Score: 0.014
  23. Begley L, Keeney D, Beheshti B, Squire JA, Kant R, Chaib H, MacDonald JW, Rhim J, Macoska JA. Concordant copy number and transcriptional activity of genes mapping to derivative chromosomes 8 during cellular immortalization in vitro. Genes Chromosomes Cancer. 2006 Feb; 45(2):136-46.
    View in: PubMed
    Score: 0.014
  24. Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell. 2005 Dec; 4(6):291-8.
    View in: PubMed
    Score: 0.013
  25. Hashemi Gheinani A, Sack BS, Bigger-Allen A, Thaker H, Atta H, Lambrinos G, Costa K, Doyle C, Gharaee-Kermani M, Patalano S, Piper M, Cotellessa JF, Vitko D, Li H, Kadayil Prabhakaran M, Cristofaro V, Froehlich J, Lee RS, Yang W, Sullivan MP, Macoska JA, Adam RM. Multiomics analysis unveils an inosine-sensitive DNA damage response in neurogenic bladder after spinal cord injury. JCI Insight. 2025 Jun 23; 10(12).
    View in: PubMed
    Score: 0.013
  26. Labaf M, Han W, Zhang S, Liu M, Patten ND, Li M, Patalano S, Macoska JA, Balk SP, Han D, Zarringhalam K, Cai C. Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed Rb-Proficient and Rb-Deficient Cells. Mol Cancer Ther. 2025 May 02; 24(5):772-783.
    View in: PubMed
    Score: 0.013
  27. Berger N, Kugler B, Han D, Li M, Nguyen P, Anderson M, Patalano-Salsman S, Zhang S, Macoska J, Cai C, Zou K. Voluntary Exercise Attenuates Tumor Growth in a Preclinical Model of Castration-Resistant Prostate Cancer. Med Sci Sports Exerc. 2025 Aug 01; 57(8):1732-1742.
    View in: PubMed
    Score: 0.013
  28. Macoska JA, Paris P, Collins C, Andaya A, Beheshti B, Chaib H, Kant R, Begley L, MacDonald JW, Squire JA. Evolution of 8p loss in transformed human prostate epithelial cells. Cancer Genet Cytogenet. 2004 Oct 01; 154(1):36-43.
    View in: PubMed
    Score: 0.012
  29. Wang Z, Townley SL, Zhang S, Liu M, Li M, Labaf M, Patalano S, Venkataramani K, Siegfried KR, Macoska JA, Han D, Gao S, Risbridger GP, Taylor RA, Lawrence MG, He HH, Selth LA, Cai C. FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer. Nat Commun. 2024 Jun 08; 15(1):4914.
    View in: PubMed
    Score: 0.012
  30. Han D, Labaf M, Zhao Y, Owiredu J, Zhang S, Patel K, Venkataramani K, Steinfeld JS, Han W, Li M, Liu M, Wang Z, Besschetnova A, Patalano S, Mulhearn MJ, Macoska JA, Yuan X, Balk SP, Nelson PS, Plymate SR, Gao S, Siegfried KR, Liu R, Stangis MM, Foxa G, Czernik PJ, Williams BO, Zarringhalam K, Li X, Cai C. Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs. J Clin Invest. 2024 Apr 30; 134(11).
    View in: PubMed
    Score: 0.012
  31. Besschetnova A, Han W, Liu M, Gao Y, Li M, Wang Z, Labaf M, Patalano S, Venkataramani K, Muriph RE, Macoska JA, Siegfried KR, Evans J, Balk SP, Gao S, Han D, Cai C. Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression. Cancer Res Commun. 2023 08; 3(8):1716-1730.
    View in: PubMed
    Score: 0.012
  32. Wang Z, Petricca J, Liu M, Zhang S, Chen S, Li M, Besschetnova A, Patalano S, Venkataramani K, Siegfried KR, Macoska JA, Han D, Gao S, Vedadi M, Arrowsmith CH, He HH, Cai C. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1. Proc Natl Acad Sci U S A. 2023 08 15; 120(33):e2220472120.
    View in: PubMed
    Score: 0.011
  33. Chaib H, MacDonald JW, Vessella RL, Washburn JG, Quinn JE, Odman A, Rubin MA, Macoska JA. Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors. Genes Chromosomes Cancer. 2003 Jul; 37(3):306-13.
    View in: PubMed
    Score: 0.011
  34. Li M, Liu M, Han W, Wang Z, Han D, Patalano S, Macoska JA, Balk SP, He HH, Corey E, Gao S, Cai C. LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer. Cancer Res. 2023 05 15; 83(10):1684-1698.
    View in: PubMed
    Score: 0.011
  35. Han W, Liu M, Han D, Toure AA, Li M, Besschetnova A, Wang Z, Patalano S, Macoska JA, Lam HM, Corey E, He HH, Gao S, Balk SP, Cai C. Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. Mol Ther. 2022 04 06; 30(4):1628-1644.
    View in: PubMed
    Score: 0.010
  36. Han W, Liu M, Han D, Li M, Toure AA, Wang Z, Besschetnova A, Patalano S, Macoska JA, Gao S, He HH, Cai C. RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition. Oncogene. 2022 Feb; 41(6):852-864.
    View in: PubMed
    Score: 0.010
  37. Han D, Owiredu JN, Healy BM, Li M, Labaf M, Steinfeld JS, Patalano S, Gao S, Liu M, Macoska JA, Zarringhalam K, Siegfried KR, Yuan X, Rebbeck TR, Cai C. Susceptibility-Associated Genetic Variation in NEDD9 Contributes to Prostate Cancer Initiation and Progression. Cancer Res. 2021 07 15; 81(14):3766-3776.
    View in: PubMed
    Score: 0.010
  38. Gao S, Chen S, Han D, Wang Z, Li M, Han W, Besschetnova A, Liu M, Zhou F, Barrett D, Luong MP, Owiredu J, Liang Y, Ahmed M, Petricca J, Patalano S, Macoska JA, Corey E, Chen S, Balk SP, He HH, Cai C. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nat Genet. 2020 10; 52(10):1011-1017.
    View in: PubMed
    Score: 0.009
  39. Ruetten H, Wegner KA, Kennedy CL, Turco A, Zhang HL, Wang P, Sandhu J, Sandhu S, Morkrid J, Wang Z, Macoska J, Peterson RE, Bjorling DE, Ricke WA, Marker PC, Vezina CM. Impact of sex, androgens, and prostate size on C57BL/6J mouse urinary physiology: urethral histology. Am J Physiol Renal Physiol. 2020 03 01; 318(3):F617-F627.
    View in: PubMed
    Score: 0.009
  40. Ruetten H, Wegner KA, Zhang HL, Wang P, Sandhu J, Sandhu S, Morkrid J, Mueller B, Wang Z, Macoska J, Peterson RE, Bjorling DE, Ricke WA, Marker PC, Vezina CM. Insight and Resources From a Study of the "Impact of Sex, Androgens, and Prostate Size on C57BL/6J Mouse Urinary Physiology. Toxicol Pathol. 2019 12; 47(8):1038-1042.
    View in: PubMed
    Score: 0.009
  41. Liu TT, Rodgers AC, Nicholson TM, Macoska JA, Marker PC, Vezina CM, Bjorling DE, Roldan-Alzate A, Hernando D, Lloyd GL, Hacker TA, Ricke WA. Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing. J Vis Exp. 2019 08 14; (150).
    View in: PubMed
    Score: 0.009
  42. Ruetten H, Wegner KA, Zhang HL, Wang P, Sandhu J, Sandhu S, Mueller B, Wang Z, Macoska J, Peterson RE, Bjorling DE, Ricke WA, Marker PC, Vezina CM. Impact of sex, androgens, and prostate size on C57BL/6J mouse urinary physiology: functional assessment. Am J Physiol Renal Physiol. 2019 10 01; 317(4):F996-F1009.
    View in: PubMed
    Score: 0.009
  43. Gao S, Chen S, Han D, Barrett D, Han W, Ahmed M, Patalano S, Macoska JA, He HH, Cai C. Forkhead domain mutations in FOXA1 drive prostate cancer progression. Cell Res. 2019 Sep; 29(9):770-772.
    View in: PubMed
    Score: 0.009
  44. Zhou F, Gao S, Han D, Han W, Chen S, Patalano S, Macoska JA, He HH, Cai C. TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells. Oncogene. 2019 05; 38(22):4397-4411.
    View in: PubMed
    Score: 0.008
  45. Wegner KA, Abler LL, Oakes SR, Mehta GS, Ritter KE, Hill WG, Zwaans BM, Lamb LE, Wang Z, Bjorling DE, Ricke WA, Macoska J, Marker PC, Southard-Smith EM, Eliceiri KW, Vezina CM. Void spot assay procedural optimization and software for rapid and objective quantification of rodent voiding function, including overlapping urine spots. Am J Physiol Renal Physiol. 2018 10 01; 315(4):F1067-F1080.
    View in: PubMed
    Score: 0.008
  46. Han D, Gao S, Valencia K, Owiredu J, Han W, de Waal E, Macoska JA, Cai C. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer. Oncotarget. 2017 Jan 24; 8(4):6796-6808.
    View in: PubMed
    Score: 0.007
  47. Gao S, Gao Y, He HH, Han D, Han W, Avery A, Macoska JA, Liu X, Chen S, Ma F, Chen S, Balk SP, Cai C. Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. Cell Rep. 2016 10 18; 17(4):966-976.
    View in: PubMed
    Score: 0.007
  48. Hao L, Greer T, Page D, Shi Y, Vezina CM, Macoska JA, Marker PC, Bjorling DE, Bushman W, Ricke WA, Li L. In-Depth Characterization and Validation of Human Urine Metabolomes Reveal Novel Metabolic Signatures of Lower Urinary Tract Symptoms. Sci Rep. 2016 08 09; 6:30869.
    View in: PubMed
    Score: 0.007
  49. Ricke WA, Macoska JA, Cunha GR. Developmental, cellular and molecular biology of benign prostatic hyperplasia. Differentiation. 2011 Nov-Dec; 82(4-5):165-7.
    View in: PubMed
    Score: 0.005
  50. Cooper CR, Graves B, Pruitt F, Chaib H, Lynch JE, Cox AK, Sequeria L, van Golen KL, Evans A, Czymmek K, Bullard RS, Donald CD, Sol-Church K, Gendernalik JD, Weksler B, Farach-Carson MC, Macoska JA, Sikes RA, Pienta KJ. Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF-alpha. J Cell Biochem. 2008 Aug 15; 104(6):2298-309.
    View in: PubMed
    Score: 0.004
  51. Sarma AV, Burke JP, Jacobson DJ, McGree ME, St Sauver J, Girman CJ, Lieber MM, Herman W, Macoska J, Montie JE, Jacobsen SJ. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men. Diabetes Care. 2008 Mar; 31(3):476-82.
    View in: PubMed
    Score: 0.004
  52. Barrett JM, Rovedo MA, Tajuddin AM, Jilling T, Macoska JA, MacDonald J, Mangold KA, Kaul KL. Prostate cancer cells regulate growth and differentiation of bone marrow endothelial cells through TGFbeta and its receptor, TGFbetaRII. Prostate. 2006 May 01; 66(6):632-50.
    View in: PubMed
    Score: 0.003
  53. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate. 2003 Jun 01; 55(4):239-46.
    View in: PubMed
    Score: 0.003
  54. Donald CD, Sun CQ, Lim SD, Macoska J, Cohen C, Amin MB, Young AN, Ganz TA, Marshall FF, Petros JA. Cancer-specific loss of beta-defensin 1 in renal and prostatic carcinomas. Lab Invest. 2003 Apr; 83(4):501-5.
    View in: PubMed
    Score: 0.003
  55. True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, Macoska JA, Norwood T, Liu A, Ellis W, Lange P, Vessella R. A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am J Pathol. 2002 Aug; 161(2):705-15.
    View in: PubMed
    Score: 0.003
  56. Lee YG, Macoska JA, Korenchuk S, Pienta KJ. MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia. 2002 Jul-Aug; 4(4):291-4.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.